BioCentury
ARTICLE | Company News

Shire launches Natpara in the U.S.

April 2, 2015 2:06 AM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) announced the U.S. launch of Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. The wholesale acquisition cost (WAC) of the recombinant human parathyroid hormone 1-84 (PTH) is $7,916.67 per 28-day package.

The chronic therapy is the first hormone replacement approved for the indication (see BioCentury Extra, Jan. 23). ...